AMPE | Ampio Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: AMEX)

Day's Range	0.0004 - 0.0022
52 Week Range	0.0001 - 7.47
Beta	2.12
Implied Volatility	690.77%
IV Rank	5.86%
Day's Volume	40
Average Volume	796
Shares Outstanding	1,135,360
Market Cap	2,498
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-03-31

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-10.66
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6
Country	USA
Website	AMPE

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

AMPE's peers: LSTA

*Chart delayed

Analyzing fundamentals for AMPE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see AMPE Fundamentals page.

Watching at AMPE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on AMPE Technicals page.